A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF THE INTRAVENOUS NITROXYL PRODRUG, CXL-1427

Robert Noveck, Shiyin Foo,Doug Cowart, Robert Venuti,Jeffrey Guptill

Journal of the American College of Cardiology（2015）

引用 15|浏览7

暂无评分

摘要

CXL-1427 is a 2nd generation intravenous prodrug that delivers nitroxyl (HNO). HNO has been shown to have multiple cardiovascular effects, including inotropy, lusitropy and peripheral vasodilation, suggesting benefit in the treatment of acute heart failure patients.The objectives of this phase 1

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要